← Back to Search

Other

Alcohol, ethyl, moderate dose for HIV

N/A
Recruiting
Led By Mollie Monnig, PhD
Research Sponsored by Brown University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 hours
Awards & highlights

Study Summary

This trial will study the effects of moderate alcohol consumption on HIV patients, specifically looking at inflammation and neuroinflammation.

Eligible Conditions
  • HIV
  • Alcohol Consumption

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Cerebral metabolites
Plasma biomarker of microbial translocation
Plasma biomarkers of immune activation
+1 more
Secondary outcome measures
Cognitive functioning
Subjective intoxication

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Alcohol, ethyl, moderate doseExperimental Treatment1 Intervention
0.6 gram ethyl alcohol per kilogram of body weight
Group II: PlaceboPlacebo Group1 Intervention
0 gram ethyl alcohol per kilogram of body weight

Find a Location

Who is running the clinical trial?

Brown UniversityLead Sponsor
456 Previous Clinical Trials
558,274 Total Patients Enrolled
The Miriam HospitalOTHER
238 Previous Clinical Trials
37,405 Total Patients Enrolled
National Institute of General Medical Sciences (NIGMS)NIH
269 Previous Clinical Trials
247,042 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~18 spots leftby Apr 2025